Filter by:
Oral APX3330 treatment reduces L-CNV lesions in preclinical mouse model and confirms Phase 2 DR/DME clinical dose with sufficient distribution to human retina using PBPK modeling
APX3330
Indiana University School of Medicine
Bridging population pharmacokinetic and physiologically based pharmacokinetic approaches to evaluate APX3330 disposition
APX3330
Indiana University School of Medicine
Inhibition of APE1/Ref-1 Redox Signaling Alleviates Intestinal Dysfunction and Damage to Myenteric Neurons in a Mouse Model of Spontaneous Chronic Colitis
APX3330
Inflammatory Bowel Disease 2020
The multifunctional APE1 DNA repair-redox signaling protein as a drug target in human disease
APX3330
Drug Discovery Today 2020
A Phase 1 Study of the APE1 Protein Inhibitor APX3330 in Patients with Advanced Solid Tumors
APX3330
Presented at the American Society of Clinical Oncology (Chicago)
APX3330 Promotes Neurorestorative Effects after Stroke in Type One Diabetic Rats
APX3330
Aging and Disease 2018